生成双人源化 BLT（骨髓、肝脏、胸腺）小鼠模型

Executive Industry Relevance

The double humanized BLT-mouse model enables mechanistic de-risking of immunotherapies by providing a disease-relevant system with functional human immune cells and a stable human-like gut microbiome. This supports target validation and predictive confidence in preclinical models by recapitulating human immune-microbiome interactions critical for drug response and safety assessment. The model enhances translational continuity from discovery through preclinical stages, reducing late-stage biological risk in immune-modulating therapies.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses involving human immune cell development and function.
• Scientific Value: Supports biological de-risking by clarifying pathway activity in a human immune context.
• Scientific Value: Facilitates functional target validation through assessment of immune cell reconstitution and differentiation.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems with stable human immune and microbiome engraftment for downstream screening.
• Operational Value: Ensures assay standardization and reproducibility through consistent human immune cell readouts via flow cytometry.
• Operational Value: Enables quantitative dependent variable measurements of immune cell populations for compound evaluation.

Translational & Preclinical Research

• Scientific Value: Provides a disease-relevant system to study human immune-microbiome interactions in vivo.
• Scientific Value: Supports mechanistic de-risking by modeling immune responses influenced by gut microbiota.
• Operational Value: Enables risk-adjusted advancement decisions based on human immune cell reconstitution levels.

Pipeline & Workflow Integration

The model integrates into the discovery continuum from target validation through preclinical research, supporting hypothesis testing and pathway clarification in immunology and microbiome-modulating therapies.

• Discovery Biology: Supports hypothesis testing of immune targets and pathway modulation using human immune cell readouts.
• Screening: Delivers assay readiness through stable engraftment of human hematopoietic stem cells and microbiome.
• Analytics: Enables quantitative flow cytometry measurements of CD45+, CD3+, CD4+, CD8+, CD19+ immune cells to compare experimental conditions.
• Translational Research: Connects discovery to preclinical validation via continuous monitoring of human immune system functionality.
• Enterprise Reuse: Serves as a reusable platform for iterative testing of immunomodulatory compounds and microbiome-based therapeutics.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence in target validation through functional human immune system reconstitution.
• Operational Value: Standardization and reproducibility via defined engraftment protocols and immune cell assessment.
• Strategic Value: Improved go/no-go decisions by reducing mechanistic ambiguity in immune-mediated drug effects.
• Portfolio Impact: Risk-adjusted prioritization based on human immune cell engraftment levels and microbiome stability.

Implementation Considerations

• Requires expertise in murine surgery, tissue implantation, and hematopoietic stem cell handling.
• Dependent on irradiation equipment, sterile surgical tools, and flow cytometry infrastructure.
• Necessitates cross-team standardization between immunology, microbiology, and animal care groups.
• Involves adaptation considerations for different human fetal tissue sources and stem cell batches.
• Limited by the 9–12 week engraftment timeline and antibiotic-dependent microbiome conditioning.

Biopharma FAQs